Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

NCT03571828 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03571828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
October 29, 2018
Completion date
January 12, 2022
Enrollment
10 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma(dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl)